Join Aura Biosciences for a virtual KOL event, featuring Carol Shields, MD (Wills Eye Hospital), Hakan Demirci, MD (University of Michigan), and Mandeep Sagoo, MB, PhD, FRCS (Ed), FRCOPTH (Moorfields Eye Hospital) who will discuss the unmet medical need and current treatment landscape for patients suffering from ocular cancers, such as primary uveal melanoma, metastases to the choroid, and cancers of the ocular surface.

The event will also highlight Aura’s ocular oncology pipeline, focusing on its lead candidate bel-sar, which is currently in development as a potential vision-sparing therapy in the global Phase 3 CoMpass trial for the first-line treatment of adult patients with early-stage uveal melanoma.

Aura’s Therapeutic Area Head Ocular Oncology Anthony Daniels, MD will join the KOLs for a panel discussion moderated by Chris Howerton, PhD from LifeSci Advisors.

A live question and answer session will follow the formal presentations.